Alogenní transplantace krvetvorných buněk po režimu s redukovanou intenzitou ve složení busulfan, fludarabin a antithymocytární globulin (ATG Fresenius): dlouhodobé výsledky

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Title in English Long-term results of allogeneic hematopoietic stem cell transplantation after a reduced-intensity conditioning busulfan, fludarabine, and antithymocyte globulin
Authors

BRYCHTOVÁ Yvona KREJČÍ Marta DOUBEK Michael TOMIŠKA Miroslav NAVRÁTIL Milan RÁČIL Zdeněk DVOŘÁKOVÁ Dana HORKÝ Ondřej LENGEROVÁ Martina POSPÍŠILOVÁ Šárka MAYER Jiří

Year of publication 2011
Type Article in Periodical
Magazine / Source Transfuze a hematologie dnes
MU Faculty or unit

Faculty of Medicine

Citation
Field Oncology and hematology
Keywords reduced-intensity conditioning; fludarabine; busufan; antithymocyte globulin
Description Reduced-intensity conditioning (RIC) is being widely used for allogeneic stem cell transplantation (SCT). Here we present our long-term experience with RIC regimen consisting of fludarabine (6x30 mg/m2), busulfan (2x4 mg/kg) and antithymocyte globulin (ATG Fresenius, 4x10 mg/kg) (Flu-Bu-ATG) at cohort of 71 patients (pts) with various hematological malignancies, 65 pts had unrelated donor, 6 related donor. Patients were transplanted in period 1998-2008, aim of our work was to evaluate effectivity and toxicity of RIC Flu-Bu-ATG. Median age was 50 years. Overall response rate was 87%; 83% of pts achieved complete and 4% partial response. The incidence of acute and chronic GVHD was 35% and 52%. The cumulative incidence of non-relapse mortality after 1 year and 4 years were 8% and 14%, respectively. With median follow-up of 55.0 months after SCT, 2- and 4-year event-free survival (EFS) was 49.0% and 40.3%, overall survival (OS) was 73.2% and 62.6%. Gender, age at SCT, type of donor, disease status at SCT, previous autologous transplantation, achievement of complete chimerism to day +100 did not significantly influence EFS and OS. On multivariate analysis, no presence of chronic GVHD (p = 0.029, HR:2.5), other diagnosis than CML (p = 0.018, HR:4.6) and dose of CD34+ cells lower than 5x106/kg (p = 0.010, HR:2.8) are statistically significant for shorter OS. In conclusion, the Flu-Bu-ATG protocol can be considered as a RIC regimen combining effective disease control and acceptable toxicity profil.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.